Axio BioPharma is a CDMO transforming biopharma manufacturing. We accelerate the development of antibodies and proteins. Cutting development from years to hours
Axio BioPharma is attending the LSX Investival Showcase USA in Miami, taking place March 10–11. We look forward to connecting with investors, sponsors, and strategic partners who are focused on building durable, network-driven infrastructure for the next generation of biologics!
Today is Employee Appreciation Day, and at Axio BioPharma we want to recognize the team behind our mission to accelerate biologics from concept to clinic.
#EmployeeAppreciation
Today is Employee Appreciation Day, and at Axio BioPharma we want to recognize the team behind our mission to accelerate biologics from concept to clinic.
#EmployeeAppreciation
Employee Highlight: Tristan McAloon
As Director of Commercial Operations at Axio BioPharma, Tristan helps accelerate biologics through smarter, high-throughput processes. For him, the mission is personal, advancing therapies for patients still waiting.
#BiopharmaLeadership
As we enter 2026, biopharma is moving from AI experimentation to measurable impact. The next phase will be driven by better data, earlier signals, and reduced manufacturing variability. We’re excited to help shape what’s ahead!
#Biomanufacturing#Biologics#AIinBiotech #2026
Looking forward to reconnecting in January to continue conversations on how AI and better data foundations can ease capacity pressure across the industry.
Wishing our partners and peers a restful holiday season.
#Biomanufacturing#LifeSciences#TeamAxioBioPharma
Axio BioPharma will be attending #JPM2026 in San Francisco.
As biologics manufacturing faces capacity limits and complexity, we’re focused on how practical AI can reduce development risk and improve decisions earlier in the lifecycle.
Looking forward to seeing you there!
Today, we honor the courage, dedication, and sacrifice of all who have served in the U.S. Armed Forces.
Your service and perseverance inspire us every day.
Thank you, veterans and families, for your unwavering commitment. 🇺🇸
#VeteransDay#ThankYouVeterans#AxioBioPharma
Next stop: #CPHIWorldwide in Frankfurt! 🇩🇪
The Axio BioPharma team is heading to one of the biggest pharma innovation events to share how AI-powered biomanufacturing is redefining speed, scalability & quality in biologics.
If you’ll be attending, we’d love to connect!
We’re headed to Madison for the 2025 Wisconsin Biohealth Summit!
Proud to sponsor lunch + showcase how Axio BioPharma is using AI to accelerate biologics development from sequence to scalable manufacturing.
Stop by booth #200 during lunch to connect!
Oct 14–15 | Madison, WI
What a week at #FestivalOfBiologics!
Great conversations with innovators, partners & leaders on the future of #biomanufacturing—where speed, scalability & innovation matter most.
Thanks to all who connected with us about Axio’s AI-powered approach in Basel! 🚀
#AIinBiotech
At Axio BioPharma, our AI-powered engine delivers proteins in just 3–5 weeks (vs. months).
📄 Check out our one-pager to see how we do it + what sets us apart: https://t.co/DuvPfqanBq
At the Festival of Biologics this week? Let’s connect!
#Biomanufacturing#AI
Excited that our CEO, Justin Byers, will be at the Festival of Biologics in Basel on Sept 30! 🚀
At Axio BioPharma, we’re using AI-driven process development to make biologics faster, smarter & more predictable.
Let’s connect in Basel!
#FestivalofBiologics#Biopharma#AI
Join us Oct. 16 for a webinar w/ Likarda, Forward Biolabs & Axio BioPharma.
Topics:
✅ Drug delivery risks
✅ AI speeding development
✅ Mfg bottlenecks & reshoring
✅ Integrating delivery + AI
👉 Register: https://t.co/Q0kUZZI7nK
#AIinPharma#DrugDevelopment#Biomanufacturing
.@MWBionetworks Trending News: Axio BioPharma and Likarda Announce Strategic Partnership to Accelerate Biologic Drug Development and Delivery https://t.co/eJfLNnAkAj #News#biotech
“What’s really setting @AxioBiopharma apart is that we’re using #AI at the foundation of the company, specifically we’re using AI in the #processdevelopment cycle,” said CEO Justin Byers, who previously worked as a #processdevelopment scientist.
🎙https://t.co/X2WiOq0Eoh
Axio BioPharma is proud to announce its strategic partnership with eMBR Genomics to bring MKLP1 Pro™ antibodies to the global research community! Together, we’re advancing MBR research and cancer diagnostics.
Discover more: https://t.co/9Ftk2mD3Fv
#CancerDiagnostics#MKLP1Pro